The potential of oncolytic viruses as a novel approach to
cancer treatment is exciting and offers a targeted approach that
holds promise for overcoming treatment resistance and achieving
durable responses in a range of malignancies.
LAS
VEGAS, July 1, 2024 /PRNewswire/ -- Oncolytic
viruses are either RNA or DNA viruses. RNA viruses such as
reoviruses, paramyxoviruses, and picornaviruses, which encode only
a few genes, often undergo rapid proliferation and lysis of tumor
cells. On the other hand, oncolytic DNA viruses such as herpes
viruses, adenoviruses, or poxviruses allow for the insertion of
multiple foreign genes but are slower in replication and
amplification.
Among the selected cancers, bladder cancer accounted for the
maximum cases as compared to other selected indications in 2023
among the 7MM. As per the DelveInsight assessment, in 2023, the
total incident cases of melanoma, non-melanoma skin cancer,
pancreatic cancer, renal cell carcinoma, prostate cancer, brain
cancer, bladder cancer, and ovarian cancer combined in the United States were 1.1 million.
Currently, only two oncolytic virus therapies are approved,
namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen) and
DELYTACT (teserpaturev/G47∆; Daiichi Sankyo).
Learn more about the FDA-approved oncolytic viruses @
Oncolytic Viruses Cancer Treatment
IMLYGIC (T-VEC), developed by Amgen, became the
first oncolytic virus to receive approval from the FDA in 2015. It
is indicated for the local treatment of unresectable cutaneous,
subcutaneous, and nodal lesions in patients with recurrent melanoma
following initial surgery. Subsequently, in December 2015, the European Commission (EC) also
approved for its use in treating adults with unresectable melanoma
that has regionally or distantly metastasized (Stage IIIB, IIIC,
and IVM1a), excluding bone, brain, lung, or other visceral
diseases. This genetically modified herpes simplex virus type 1 is
engineered to replicate within tumors and express an
immune-stimulating protein known as granulocyte-macrophage
colony-stimulating factor (GM-CSF).
DELYTACT (G47Δ) is a modified form of herpes simplex
virus type 1 (HSV-1) with three mutations, designed to selectively
replicate within cancer cells. In 2021, it received provisional
approval from the Japan Ministry of Health, Labour and Welfare
(MHLW) for hospital-based commercialization, specifically for
treating malignant glioma patients over 7 years. This approval
followed a Phase II trial demonstrating improved one-year survival
rates among patients with recurrent glioblastoma, previously
treated with radiotherapy and temozolomide chemotherapy. DELYTACT
marks the world's first oncolytic virus therapy for brain cancer
and only the third globally available oncolytic virus
treatment.
To learn more about oncolytic viruses cancer treatment options,
visit @ Oncolytic Virus Cancer Therapy
The field of oncolytic virus therapy is still developing.
Further research is needed to determine their long-term efficacy
and potential challenges. Still, early results seem encouraging,
suggesting that oncolytic viruses may become a powerful tool for
the treatment of patients with cancer.
Presently, oncolytic virus therapy is only approved for melanoma
and malignant glioma (in Japan).
However, the pipeline suggests its emergence as a potential
treatment for various cancers, including ovarian cancer, non-small
cell lung cancer, breast cancer, renal cell carcinoma, and
others.
The pipeline for oncolytic viruses is robust, with major
pharmaceutical companies such as Replimune (RP1), Genelux (Olvi-Vec), Candel Therapeutics
(CAN-2409), Imugene (CF33-HNIS), EpicentRx (AdAPT-001), and
others actively engaged in research to enhance cancer treatment
options.
Discover which therapies are expected to grab major oncolytic
virus therapy market share @ Oncolytic Virus Therapy Market
Report
Olvi-Vec is a proprietary oncolytic vaccinia virus
engineered to enhance safety, tumor selectivity, and therapeutic
potential. Originally a non-human pathogen used in the smallpox
vaccine, the vaccinia virus induces immunogenic cell death and
activates the immune system for long-term cancer immunotherapy.
According to Genelux's recent corporate presentation, topline
results for the Phase III OnPrime/GOG-3076 study are expected in
the second half of 2025. In November
2023, Genelux announced that the US FDA granted Fast Track
Designation for Olvi-Vec (olvimulogene nanivacirepvec) in treating
patients with platinum-resistant/refractory ovarian cancer. The
drug is currently in Phase III clinical development, with the study
anticipated to be completed by 2026.
RP1 is
Replimune's leading product candidate, developed from a
proprietary new strain of herpes simplex virus. It has been
genetically modified and enhanced with a fusogenic protein (GALV-GP
R-) and GM-CSF to enhance tumor-killing potency, improve the
immunogenicity of tumor cell death, and stimulate a systemic
anti-tumor immune response. In April
2024, Replimune presented interim results from ARTACUS, a
Phase I/II clinical trial testing RP1
monotherapy for skin cancers in patients who have undergone solid
organ or hematopoietic cell transplants. Currently, RP1 is in the Phase II IGNYTE study, a
multi-cohort clinical trial combining RP1 with OPDIVO.
AdAPT-001 is an experimental immunotherapy featuring
a TGF-β receptor-immunoglobulin Fc fusion trap. It is designed to
neutralize isoforms 1 and 3 of the profibrotic, proangiogenic,
prohypoxic, and immunosuppressive cytokine, TGF-β, and make
resistant tumors more responsive to checkpoint blockade. In the
ongoing Phase I/II BETA PRIME trial, AdAPT-001 is being
administered alone and in combination with checkpoint inhibitors to
patients with treatment-resistant tumors. Notably, AdAPT-001
combined with checkpoint inhibitors has shown improved toxicity and
adverse event profiles compared to the typical results seen with
checkpoint inhibitors alone.
Discover more about oncolytic viruses in development @
Oncolytic Viruses Cancer Therapy Clinical Trials
The anticipated launch of these emerging therapies are poised to
transform the market landscape in the coming years. As these
cutting-edge therapies continue to mature and gain regulatory
approval, they are expected to reshape the oncolytic virus cancer
therapy market landscape, offering new standards of care and
unlocking opportunities for medical innovation and economic
growth.
DelveInsight estimates that the market size for oncolytic virus
therapy is expected to grow with a significant CAGR by 2034. As per
DelveInsight, the United States
accounts for the largest oncolytic virus market size accounting for
more than 70% of the total market, in comparison to EU4
(Germany, Spain, Italy,
France), the United Kingdom, and Japan. Among all the emerging oncolytic virus
therapies, RP1 is the most promising
therapy accounting for ~40% of the oncolytic virus market in
the coming decade due to its high efficacy.
DelveInsight's latest published market report titled as
Oncolytic Virus Market Size, Target Population, Competitive
Landscape & Market Forecast – 2034 will help you to
discover which market leader is going to capture the largest market
share. The report provides comprehensive insights into the
oncolytic virus country-specific treatment guidelines, patient pool
analysis, and epidemiology forecast to help understand the key
opportunities and assess the market's underlying potential. The
oncolytic virus market report proffers epidemiological
analysis for the study period 2020–2034 in the 7MM segmented
into:
- Total Incident Cases of Selected Cancer Types
- Target Patient Pool of Oncolytic Virus Cancer Therapy by Cancer
Types
- Total Treated Cases by Line of Therapies
The report provides an edge while developing business strategies
by understanding trends shaping and driving the 7MM oncolytic virus
market. Highlights include:
- 11-year Forecast
- 7MM Analysis
- Epidemiology-based Market Forecasting
- Historical and Forecasted Market Analysis upto 2034
- Emerging Drug Market Uptake
- Peak Sales Analysis
- Key Cross Competition Analysis
- Industry Expert's Opinion
- Access and Reimbursement
Download this oncolytic virus market report to assess the
epidemiology forecasts, understand the patient journeys, know KOLs'
opinions about the upcoming treatment paradigms, and determine the
factors contributing to the shift in the oncolytic virus market.
Also, stay abreast of the mitigating factors to improve your market
position in the oncolytic virus therapeutic space.
Related Reports
Oncolytic Virus Competitive Landscape
Oncolytic Virus Competitive Landscape – 2024 report provides
comprehensive insights about the pipeline landscape, pipeline drug
profiles, including clinical and non-clinical stage products, and
the key oncolytic virus companies, including Genelux
Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen
Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology,
Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech,
Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira
Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma,
ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly
Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera
Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas
Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin
Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira
Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN
Biosciences, Candel therapeutics, Sorrento Therapeutics, Imugene
Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics,
Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse
Therapeutics, among others.
Oncology Drugs Market
Oncology Drugs Market Insight, Competitive
Landscape, and Market Forecast – 2030 report delivers an
in-depth understanding of market trends, market drivers, market
barriers, and key oncology drugs companies, including
GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche
Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis
AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead
Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex
Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma
Inc., Genentech, Inc., Sandoz International GmbH, BeiGene,
among others.
Melanoma Market
Melanoma Market Insights, Epidemiology, and Market
Forecast – 2032 report deliver an in-depth understanding of the
disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key
melanoma companies including IO Biotech, Merck Sharp &
Dohme, Eisai, Regeneron Pharmaceuticals, Iovance Biotherapeutics,
Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank
Pharmaceuticals, Taiga Biotechnologies, Inc., Aivita Biomedical,
Inc., Genentech, Inc., Dana-Farber Cancer Institute, BioMed Valley
Discoveries, Inc, Amgen, Checkmate Pharmaceuticals, Astellas Pharma
Inc, Galectin Therapeutics Inc., Eucure (Beijing) Biopharma Co., Ltd, Mologen AG,
Ultimovacs ASA, Seagen Inc., MedImmune LLC, OnKure, Inc., Syntrix
Biosystems, Inc., Anaveon AG, iOx Therapeutics, Portage Biotech,
ModernaTX, Inc., Nektar Therapeutics, BioNTech SE, Sapience
Therapeutics, HUYABIO International, LLC., Provectus
Biopharmaceuticals, Inc., Cantargia AB, Turnstone Biologics, Corp.,
Aura Biosciences, F-star Therapeutics, Inc., Day One
Biopharmaceuticals, Inc., Kinnate Biopharma, Xencor, Inc., HiFiBiO
Therapeutics, among others.
Pancreatic Cancer Market
Pancreatic Cancer Market Insights, Epidemiology, and
Market Forecast – 2034 report deliver an in-depth understanding
of the disease, historical and forecasted epidemiology, as well as
the market trends, market drivers, market barriers, and key
pancreatic cancer companies including FibroGen, OSE
Immunotherapeutics, Lokon Pharma, Oncotelic Inc., Tesaro, Inc.,
Helix BioPharma Corporation, Theradex, Tvardi Therapeutics,
Incorporated, AIM ImmunoTech Inc., BioNTech SE, Prestige Biopharma
Limited, HCW Biologics, Cantex Pharmaceuticals, XBiotech, Inc.,
Lumicell, Inc., CARsgen Therapeutics Co., Ltd., Panbela
Therapeutics, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/oncolytic-viruses-unlocking-a-new-era-in-cancer-immunotherapy--delveinsight-302186663.html
SOURCE DelveInsight Business Research, LLP